OTSUKA ABILIFY：Otsuka Pharmaceutical Co.
Otsuka Pharmaceutical Co.
2023年4月28日—FDAApprovesOtsukaandLundbeck'sABILIFYASIMTUFII®(aripiprazole),theFirst,Two-month,Long-actingInjectable(LAI)fortheTreatmentof ...。其他文章還包含有：「Abilify15mg」、「ABILIFYMAINTENA®(Aripiprazole)forExtended」、「ABILIFY®(aripiprazole)」、「FDAsignsoffonOtsukaandLundbeck'slonger」、「OTSUKAABILIFY®Tablets15mg大塚安立復®錠15毫克」、「OtsukaAbilify大塚安立復錠30毫克」、「Otsuk...
查看更多 離開網站
Abilify 15mg
http://www.lokan.com.tw
Abilify 15mg. 商品名. OTSUKA ABILIFY TABLETS 15MG. 中文名. 大塚安立復錠15毫克 ... OTSUKA PHARMACEUTICAL CO., LTD. TOKUSHIM. 藥理治療分類. 非典型抗精神病藥.
ABILIFY MAINTENA® (Aripiprazole) for Extended
https://www.otsuka-us.com
ABILIFY MAINTENA is a once-monthly injectable formulation for intramuscular use created by Otsuka and has been co-developed and ...
ABILIFY® (aripiprazole)
https://www.otsuka-us.com
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY is not approved for the treatment ...
FDA signs off on Otsuka and Lundbeck's longer
https://www.fiercepharma.com
The FDA has approved Otsuka and Lundbeck's Abilify Asimtufii, an extended-release, injectable suspension for adults with schizophrenia and ...
OTSUKA ABILIFY ® Tablets 15mg 大塚安立復® 錠15毫克
https://www.otsuka.com.tw
成人和青少年(13至17歲)的思覺失調症。 • 成人和兒童(10至17歲)的雙極性疾患之躁症發作及混合型發作，可單獨 使用或做為鋰鹽或valproate的輔助治療。
Otsuka Abilify 大塚安立復錠30毫克
https://zh-tw.sltung.com.tw
商品名稱, Otsuka Abilify ; 內含量, 30mg/tab ; 學名, Aripiprazole ; 商品外觀, 『粉紅色圓形錠,A-011 30』 ; ATC, N05AX12 ...
Otsuka Abilify 大塚安立復錠5毫克
https://zh-tw.sltung.com.tw
商品名稱, Otsuka Abilify ; 內含量, 5mg/tab ; 學名, Aripiprazole ; 商品外觀, 『藍色橢圓錠,｜,A-007 5』 ; ATC, N05AX12 ...
【篤實關懷倫理卓越】光田綜合醫院Kuang Tien General ...
https://www.ktgh.com.tw
商品名, ABILIFY (口服) 5MG, 藥品許可證, 衛署藥輸字第024046號 ... OTSUKA ABILIFY的建議起始劑量與目標劑量為每日10或15毫克，一日一次，不須考慮飲食因素。
臺北榮民總醫院桃園分院
https://www.tyvh.gov.tw
Otsuka Abilify 15mg · Aripiprazole · C · 1O018 · 28160804抗精神病藥物.
說明
https://zh.wikipedia.org